,Response,Percentage of drugs approved in 2019
0,Met PDUFA goal date*,100%
1,First cycle of review,90%
2,Approved in the United States before receiving approval in any other country,69%
3,Priority review,58%
4,Drugs for orphan diseases,44%
5,First-in-class,42%
6,Fast Track,35%
7,Breakthrough therapy,27%
8,Accelerated Approval program,19%
